Santen Corporate (EN)

2012 IR News

RSS

IR News

Changes in Significant Shareholders
Intravitreal VEGF Inhibitor "EYLEA (aflibercept) Solution for Intravitreal Injection" Released on the Market for the Treatment of Wet Age-Related Macular Degeneration
Santen Files for Manufacturing/Marketing Approval of its Anti-Allergic Ophthalmic Solution DE-114 (Generic name: Epinastine Hydrochloride)
Notice of Cancellation of Treasury Shares
Santen to Renew the Sante 40 OTC Eye Drop Series
Intravitreal VEGF Inhibitor "EYLEA Solution for Intravitreal Injection" and "EYLEA Intravitreal Injection KIT" Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan
Notice on the Establishment of a New Sales and Marketing Company in China
Eisai and Santen Enter into Option Agreement for New Ophthalmic Drugs
Notification Regarding Result and Completion of Acquisition of Treasury Stock and Tender Offer of Treasury Stock
Notice of Acquisition and Tender Offer of Treasury Stock
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
FDA Approves enVista, a Single-Piece Intraocular Lens, Made from the Glistening-Free, Hydrophobic, Acrylic Material Developed by AVS
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Announcement of the conclusion of the agreement on co-promotion of VEGF Trap-Eye (aflibercept intravitreal injection)
Notice of the Nominations for the members of the Board of Directors
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers
Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors
Notice of the appointment of Corporate Officers
Santen to Launch Sante Medical Guard OTC Eye Drop
FDA Approves ZIOPTAN (tafluprost ophthalmic solution),Merck's Once-Daily, Preservative-Free Ophthalmic Medication
Notice on the Establishment of Holding Company in Europe
Santen to Launch Nutritional Supplement Sante Lutax 20 + DHA
News Archive